Ascentage Pharma Group International (HKG:6855) raised $126.4 million from its US initial public offering of 7,325,000 American depository shares at $17.25 apiece, a Tuesday press release said.
The drugmaker also granted underwriters a 30-day option to buy up to 1,098,750 more ADSs at the IPO price, with underwriting costs deducted.
J.P. Morgan Securities and Citigroup Global Markets served as the joint book-running managers for the offering.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.